<acronym id="1166a"><blockquote id="1166a"></blockquote></acronym>
    1. <span id="1166a"></span>

        <legend id="1166a"></legend>

      1. <optgroup id="1166a"><em id="1166a"><pre id="1166a"></pre></em></optgroup><input id="1166a"></input>

      2. <optgroup id="1166a"></optgroup>
      3. <span id="1166a"></span>
      4. <span id="1166a"><video id="1166a"><b id="1166a"></b></video></span>
      5. <span id="1166a"><sup id="1166a"></sup></span>
        1. <dd id="1166a"></dd>

          <ruby id="1166a"><li id="1166a"></li></ruby>

           
           
           
           
           
          副研究員

          張立行 副研究員
          副研究員,博士生
          E-mail: Zhanglixing601@163.com
           

               2006年畢業于中國醫科大學獲得法醫學學士學位,2009年畢業于南昌大學醫學院獲得細胞生物與分子生物學碩士學位,2012年畢業于上海交通大學醫學院獲得腫瘤學博士學位。2012-2016年在上海市腫瘤研究所癌基因及相關基因國家重點實驗室工作。20168月至今任職于復旦大學附屬腫瘤醫院腫瘤研究所。近5年主持項目包括國家自然科學基金青年基金、面上項目各一項,教育部高校博士點基金項目一項,作為骨干參與科技部重點研發計劃一項并參與多項國家科技重大專項研究工作。近5年主要研究成果發表于Advanced Science, Cancer Research, PLOS Biology, Theranostics, Cell Death & Differentiation, Scientific Reports, Molecular Medicine, Chinese Journal of Cancer等雜志。


          研究領域:

            1. 乳腺腫瘤干細胞自我更新與分化的調控機制研究; 
            2. 乳腺腫瘤干細胞與免疫微環境的相互作用與靶向治療研究;
            3. 腫瘤干細胞參與化療抵抗的內源性與外源性調控與轉化研究。


          代表性論著:

          1. Zhang LX# , Qiang J# , Yang L# , Wang D, Adeel R, He X, Chen W, Sheng D, Zhou L, Jiang YZ, Li T, Du Y, Feng J, Hu X, Zhang J, Hu XC, Shao ZM, Liu S*. IL1R2 blockade suppresses breast tumorigenesis and progression by impairing USP15-dependent BMI1 stability. Advanced Science, 2020; 7(1): 1901728.

          2. Zhou L#, Wang D#, Sheng D#, Xu J, Chen W, Qin Y, Du R, Yang X, He X, Xie N*, Liu S*, Zhang LX*. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer. Theranostics, 2020; 10(5):2405-2421.

          3. Wang D#, Xu J#, Liu B, He X, Zhou L, Hu X, Qiao F, Zhang A, Xu X, Zhang H, Wicha MS, Zhang LX, Shao ZM, Liu S*. IL6 blockade potentiates the anti-tumor effects of γ–secretase inhibitors in Notch3-expressing breast cancer. Cell Death & Differentiation, 2018; 25(2):330-339.

          4. Chen W#, Qin Y#, Wang D, Zhou L, Liu Y, Chen S, Yin L, Xiao Y, Yao XH, Yang X, Ma W, Chen W, He X, Zhang LX, Yang Q, Bian X, Shao ZM, Liu S*. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biology, 2018; 16(7):e2005869.

          5. Zhang Y#, Zhang LX#, Liu XQ, Zhao FY, Ge C, Chen TY, Yao M, Li J*. Id4 promotes cell proliferation in hepatocellular carcinoma. Chinese Journal of Cancer, 2017; 36(1):19.

          6. Zhang LX, Ge C, Zhao FY, Zhang Y, Wang X, Yao M, Li J*. NRBP2 interactes with ANXA2 render hepatocellular carcinoma cell sensitive to apoptosis through Akt signaling pathway. Cancer Research,2016; 76(23):7059-7071.

          7. Zhang L#, Zhang LX#, Li H, Ge C, Zhao FY, Tian H, Chen T, Jiang G, Xie H, Cui Y, Yao M, Li J*. CXCL3 contributes to CD133+ CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation. Scientific Report, 2016; 6:27426.

          8. Zhang LX, Sun HF, Zhao FY, Lu P, Ge C, Li H, Hou H, Yan M, Chen T, Jiang G, Xie H, Cui Y, Huang X, Fan J, Yao M, Li J*. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Research, 2012; 72(16):4276-4285.

          9. Lu P, Sun HF, Zhang LX, Hou H, Zhang L, Zhao F, Ge C, Yao M, Wang T, Li J*. Isocorydine targets the drug-resistant cellular side population through PDCD4-related apoptosis in hepatocellular carcinoma. Molecular Medicine, 2012; 18:1136-1146.

           
          復旦大學腫瘤研究所 通訊地址: 東安路270號2號樓1312室 64175590-5312 Email:fuci2012@126.com
          Copyright 2013 shca.org.cn All rights reserved. 復旦大學腫瘤研究所 版權所有
          欧美日韩专区无码人妻 久久视频下载| h视频| 丁香六月| 6080yy理论片在线播放| 一本大道香蕉综合视频| 500精品一精品导航品牌| 番茄社区app二维码| 偷偷鲁青春草原视频| 夜夜春商城宫廷| 青春娱乐在线媚观看| 东方影库1250df|